ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,323.00
-0.04%
S&P ASX All Technology
3,880.20
0.04%
Brent Oil
73.36
0.71%
US Dollar vs AUD
1.53643
0.05%
Bitcoin
97,522.51
3.35%
Pepperstone
Advertisement
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU

  6. Genfit (GNFT) Share Price

Genfit

Genfit (GNFT)

Genfit SA
4.005
-0.02
( -0.50% )
Updated: 20:31:44
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
4.005
Bid
4.00
Offer
4.015
Volume
62,307
4.00 Day's Range 4.08
2.90 52 Week Range 5.86
Market Cap
199.589M
Previous Close
4.025
Open
4.025
Last Trade
670
@
4.005
Last Trade Time
20:31:44
Financial Volume
-
VWAP
-
Average Volume (3m)
329,918
Shares Outstanding
49,834,983
Dividend Yield
-
PE Ratio
-6.99
Earnings Per Share (EPS)
-0.58
Revenue
38.68M
Net Profit
-28.89M

About Genfit

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.genfit.com
Headquarters
Loos, Nord, Fra
Founded
-
Genfit is listed in the Pharmaceutical Preparations sector of the Euronext with ticker GNFT. The last closing price for Genfit was 4.03 €. Over the last year, Genfit shares have traded in a share price range of 2.90 € to 5.86 €.

Genfit currently has 49,834,983 shares in issue. The market capitalisation of Genfit is 200.59 € million. Genfit has a price to earnings ratio (PE ratio) of -6.99.

Ask ADVFN Intelligence (AI)

GNFT Latest News

More News

GENFIT fait un point d’actualité sur ses activités à l’occasion de sa participation prochaine à l’AASLD Liver Meeting® 2024

GENFIT fait un point d’actualité sur ses activités à l’occasion de sa participation prochaine à l’AASLD Liver Meeting® 2024 Programme PBC (sous licence Ipsen) : Ipsen présentera de nouvelles...

14 November 2024
UK Regulatory

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024 PBC program (licensed to Ipsen): Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch...

14 November 2024
UK Regulatory

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024

PBC program (licensed to Ipsen): Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch of Iqirvo® (elafibranor)1 on track with expectations; encouraging feedback from...

14 November 2024
GlobeNewswire Inc.

GENFIT : Information financière du troisième trimestre 2024

GENFIT : Information financière du troisième trimestre 2024 Trésorerie et équivalents de trésorerie s’élevant à 96,0 millions d’euros au 30 septembre 202459,7 millions d’euros de revenus des neuf...

08 November 2024
UK Regulatory

GENFIT Reports Third Quarter 2024 Financial Information

GENFIT Reports Third Quarter 2024 Financial Information Cash and cash equivalents totaled €96.0 million as of September 30, 2024€59.7 million in revenues for the nine months ended September 30...

08 November 2024
UK Regulatory

GENFIT Reports Third Quarter 2024 Financial Information

Cash and cash equivalents totaled €96.0 million as of September 30, 2024€59.7 million in revenues for the nine months ended September 30, 2024, including the €48.7 million milestone invoiced in...

08 November 2024
GlobeNewswire Inc.

GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval

GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval Lille (France), Cambridge...

23 September 2024
UK Regulatory

GENFIT : Iqirvo® d’Ipsen (elafibranor) reçoit l’approbation UE en tant que traitement first-in-class de la Cholangite Biliaire Primitive consécutivement à l’approbation accélérée de la FDA américaine

GENFIT : Iqirvo® d’Ipsen (elafibranor) reçoit l’approbation UE en tant que traitement first-in-class de la Cholangite Biliaire Primitive consécutivement à l’approbation accélérée de la FDA...

23 September 2024
UK Regulatory

GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 23, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to...

23 September 2024
GlobeNewswire Inc.

GENFIT : Résultats financiers du premier semestre 2024 et point sur les activités de la Société

GENFIT : Résultats financiers du premier semestre 2024 et point sur les activités de la Société Trésorerie et équivalents de trésorerie s’élevant à 61,6 millions d’euros au 30 juin 2024 n’incluant...

20 September 2024
UK Regulatory
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.885-18.09815950924.894.95543890694.21865211DE
4-1.125-21.92982456145.135.6343089324.84695135DE
120.1955.118110236223.815.863.6253299184.88489033DE
260.1854.842931937173.825.863.473368284.60069643DE
520.85527.14285714293.155.862.92661904.1943634DE
1560.82726.02265575833.1785.862.7462144903.94029017DE
260-9.895-71.187050359713.920.962.7463087035.60555573DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BIDSGascogne DS
0.0028 €
(55.56%)
22.65k
ALNEVNeovacs
0.0003 €
(50.00%)
5k
ATODSAtos SE
0.005 €
(21.95%)
11.31M
SOISOITEC
75.35 €
(18.66%)
188.54k
HYLHyloris Pharmaceuticals SA
5.90 €
(13.90%)
35.69k
EBUSEbusco Holding NV
0.9159 €
(-25.29%)
1.41M
VACBSPierre & Vacances
0.048 €
(-14.29%)
427
EMGDSEuromedis DS
0.0088 €
(-12.00%)
2.65k
ALVETTheraVet SA
0.0804 €
(-10.67%)
28.78k
ATOAtos SE
0.1728 €
(-10.23%)
2.73M
ATODSAtos SE
0.005 €
(21.95%)
11.31M
ALVERVergnet
0.0054 €
(12.50%)
7.63M
ALTDTonner Drones
0.01 €
(8.70%)
5.89M
BCPBanco Comercial Portugues SA
0.4362 €
(-0.82%)
5.84M
ATOAtos SE
0.1728 €
(-10.23%)
2.73M

Discussion

View Full Feed
aniyahsbednar aniyahsbednar 4 minutes ago
Official Website... https://cutt.ly/keKQ376J

MaxBoost Plus is a premium male enhancement supplement designed to help men improve stamina, vitality, and overall confidence. Using a powerful blend of natural ingredients, it supports testosterone levels, blood flow, and energy, empowerin
TrendTrade2016 TrendTrade2016 5 minutes ago
BDPT FIRST TRIP REVERSE SPLIT TO HIT...GET READY CLOWNS...THIS IS THE BEGINNING TO THEBIGGEST OTC RS CAMPAIGN IN A DECADE
BDPTD
Truth_is_a_tool Truth_is_a_tool 8 minutes ago
I feel a disturbance in the force too lol and I’m going to go ahead and agree. I feel we will have a PR in less than 3 hours.
KBLB
Truth_is_a_tool Truth_is_a_tool 10 minutes ago
Hi M4N , my concern was that it was in the latest prospectus that just came out but you and Mojo are probably right that it’s just a copy and paste. Either way im not really concerned as it doesn’t change my view that this company will have a breakout soon enough , whether it’s this year or the next
KBLB
Bull_Dolphin Bull_Dolphin 12 minutes ago
Yay!!!!

https://www.breitbart.com/entertainment/2024/11/20/ellen-degeneres-leaves-united-states-flees-to-england-over-trump-election/
Minddoc7 Minddoc7 13 minutes ago
Coinbase CEO Brian Armstrong Perfect For Crypto Czar Role - Charles Hoskinson

"Cardano founder Charles Hoskinson has thrown his weight behind Coinbase CEO Brian Armstrong as the best choice for a potential “crypto czar” position in the Trump administration.

The informal
COIN
Seminole Red Seminole Red 14 minutes ago
good job
cowtown jay cowtown jay 16 minutes ago
How much longer can it be before we start to see detailed stock quotes on this site (advfn) again? So many pieces of the puzzle are starting to be displayed, they have got to be near the point where they are snapped together. We've got to be generating revenue by now.

https://www.ad
aniyahsbednar aniyahsbednar 19 minutes ago
Official Website... https://cutt.ly/qeKQMuOM

VitalRize Male Enhancement is a cutting-edge supplement designed to help men regain their stamina, boost testosterone levels, and improve overall confidence. With a blend of natural and clinically tested ingredients, VitalRize offers a holi
aniyahsbednar aniyahsbednar 32 minutes ago
Official Website... https://cutt.ly/2eKQSgxD

Green Regimen Energy and Focus is a dietary supplement designed to enhance energy levels and improve mental focus naturally. Crafted with clean, plant-based ingredients, it is often marketed as a solution for those looking to maintain peak
meshcan meshcan 33 minutes ago
Great investment in R&D. Nasrat has said they will only develop the big drugs who have $1B+ annual sale. So we should see our pipeline get better and better.
ELTP
MoneyMaker111 MoneyMaker111 34 minutes ago
GME to close at or above $30 todayyy?

$GME ( Hyper Bullish / Apish )
#GME ( Hyper Bullish / Apish )
GME
infamous infamous 35 minutes ago
thats funny. on otcmarkets they talk about affordable housing. thats a euphomism for cheap homes in getto areas. 100% sure on that description IMO
ATWT
Golfbum22 Golfbum22 54 minutes ago
Hey

Pauljon4

Your village people are calling

They are missing their anger management idiot

Please grow up and do your research before you think you are smarter than anyone here.

Show some respect and stop worrying about pric
FNMA
PC retired PC retired 54 minutes ago
"Entergy" is a real business, and a big one. All the supposed distributors use the name of a real world business with added or subtracted terms, purely intended to deceive. On another note, how is Mr Szilard's install doing?, we have not heard from him in quite a while- we demand an update!!
FLCX
NotSure2 NotSure2 55 minutes ago
Lol, a judge would not be waiting for approval or not of a company before rendering his/her/zer/their etc... judgment.

The worrying part is this:

Since KG is now (always been, deep state establishment) "an ennemy" of Donald Trump, KG now falls into "allie" of the democr
NWBO
DDA DDA 1 hour ago
Some smaller amounts going through ... someone is silently pilling up
STGZ
The Danish Dude The Danish Dude 1 hour ago
I have gone down the alley of dendritic cells and trying to look at alternatives for that time, for a dendritic cell vaccine, that in any way could align with the data in the clinical trial and the results and process covered in the article.

DocLee raises good questions. I have ping-p
NWBO
SkeBallLarry SkeBallLarry 1 hour ago
Matthew Whitaker is a Great pick Steve Bannon sure is happy about it .. !!
The ELTP King The ELTP King 1 hour ago
Nasrat promised "at least" two filings by the end of 2024 which means two positive BE studies.

Both BE studies failed.

Now he did say "at least" two filing so maybe the third BE study will actually pass?

Sure would be nice to get another BE or two up to t
ELTP
236T568 236T568 1 hour ago
BREAKING:

Today’s launch by Russia of an intercontinental ballistic missile against Ukraine is the first time ever an ICBM has been launched at another state in a war.

https://x.com/visegrad24/status/1859515908172960221
TommyJ7651 TommyJ7651 1 hour ago
I don't think asking Paul about future equity financings will yield much substance. It's not like the guy has a crystal ball and he can tell us exactly how future financing rounds will emerge or what situations we might find ourselves in. He will most likely tell us the same old story about them try
FFMGF

Your Recent History

EU
GNFT
Genfit
NASDAQ
LRCX
Lam Research
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved